

10. Jul. 2008 12:00

PEARL COHEN ZEDEK LATZER

No. 4905 P. 5

APPLICANT(S): FRANKEL, Fred R et al.
SERIAL NO.: 10/660,194
FILED: September 11, 2003
Page 3

RECEIVED
CENTRAL FAX CENTER
JUL 10 2008

AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1-20. (Cancelled)

21. (Currently amended) A method of inducing an immune response against a cancer cell in a mammal, the method comprising administering to the said mammal an auxotrophic attenuated strain of *Listeria* comprising an antigen expressed by the said cancer cell, wherein said auxotrophic attenuated strain of Listeria comprises a mutation in both the dal and dat genes of Listeria.

22. (Cancelled)

23. (Currently amended) The method of claim 21, wherin the said antigen is expressed from a vector.

24. (Currently amended) The method of claim 21, wherein the said antigen is expressed from the *Listeria* genome.

25. (Currently amended) The method of claim 21, wherin the said auxotrophic attenuated strain of *Listeria* is administered orally, parenterally, intranasally, intramuscularly, intravascularly, intravenously, intrarectally, or intraperitoneally.

26. (Currently amnded) The method of claim 21, wherin the said cancer cell is a cervical cancer cell.

27-28. (Cancelled)

APPLICANT(S): FRANKEL, Fred R et al.
SERIAL NO.: 10/660,194
FILED: September 11, 2003
Page 4

29. (Previously Presented) The method of claim 21, wherein said *Listeria* is *L. monocytogenes*.

30. (Not entered) The method of claim 21, wherein said cancer cell is a melanoma cancer cell, a breast cancer cell, or a leukemia cell.

31. (Not entered) The method of claim 26, wherein said antigen is HPV E6, HPV E7, or a combination thereof.

32. (Not entered) The method of claim 21, wherein said antigen is the bcr/abl antigen.

33. (Not entered) The method of claim 21, wherein said antigen is MAGE1, M72-E or a combination thereof.

34. (Not entered) The method of claim 21, wherein said antigen is MVC-1, HER-2 or a combination thereof.

35. (Not entered) The method of claim 21, wherein said antigen is expressed as a fusion protein with listeriolysin O (LLO), phosphatidylinositol-specific phospholipase (PI-PLC), or a combination thereof.

36. (Not entered) The method of claim 21, wherein said antigen is expressed from a *Listeria* hly, p60, actA, plcA, mpl, plcB, or inlA gene promoter.

37. (Not entered) The method of claim 21, wherein said immune response is a cytotoxic T cell response.

38. (New) The method of claim 21, wherein said cancer cell is a melanoma cancer cell, a breast cancer cell, or a leukemia cell.

10. Jul. 2008 12:01

PEARL COHEN ZEDEK LATZER

No. 4905 P. 7

APPLICANT(S): FRANKEL, Fred R et al.

SERIAL NO.: 10/660,194

FILED: September 11, 2003

Page 5

39. (New) The method of claim 26, wherein said antigen is HPV E6 or HPV E7.

40. (New) The method of claim 21, wherein said antigen is the bcr/abl antigen.

41. (New) The method of claim 21, wherein said antigen is MAGE1 or M72-E.

42. (New) The method of claim 21, wherein said antigen is MVC-1 or HER-2.

43. (New) The method of claim 21, wherein said antigen is expressed as a fusion protein with listeriolysin O (LLO) or phosphatidylinositol-specific phospholipase (PI-PLC).

44. (New) The method of claim 21, wherein said antigen is expressed from a Listeria hly, p60, actA, plcA, mpl, plcB, or inlA gene promoter.